Drug Discovery World

JULY 15, 2024

Dr Alexandra Sapetschnig, Group Leader at STORM Therapeutics, described the event as one that “really set the agenda for oncology research in 2024” through the display of new approaches and methods that are expanding opportunities in drug development. This bodes well for potential future research and therapies,” she adds.

Research 130

Research Clinical Pharmacology Therapies RNA 130

Drug Discovery World

MARCH 7, 2023

She currently leads the company’s pipeline of chronic disease immunotherapeutic candidates including for Alzheimer’s, Parkinson’s, and hypercholesterolemia, as well as variant-inclusive Covid-19 booster. She has been named to Time 100 Next list, Fortune 40 under 40, and is a member of the Young Global Leaders of World Economic Forum.

International 246

International Science Pharmaceuticals DNA 246

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. a commercial stage pharmaceutical company.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. In other cases, well-established biomarker profiles enable patient enrichment strategies in early-stage clinical development.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Vial

APRIL 10, 2024

The increasing costs associated with in-house drug development have prompted biotech and pharmaceutical companies to increasingly outsource to contract research organization s (CROs) for assistance. Vial adopts a fixed-fee pricing model devoid of change orders to streamline cost-effectiveness in drug development.

Clinical Trials 52

Clinical Trials Trials Compliance Clinical Research 52

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? IRL1117 is expected to be ready to move into clinical development at the end of 2024/first half 2025.

Disease 52

Disease Drugs Treatment Drug Development 52

Conversations in Drug Development Trends

MAY 14, 2024

As the strategists for Worldwide Clinical Trials’ rare disease sponsors, we design customized solutions that make a difference in achieving successful outcomes. Our approach is informed by our combined 30+ years in rare disease clinical development and our time in various stakeholder roles, such as scientists, CRAs, and project managers.

Disease 81

Disease Clinical Trials Trials Pharmaceutical Companies 81

Drug Discovery World

OCTOBER 16, 2023

From the Beatson Institute for Cancer Research in Glasgow, to Edinburgh Drug Discovery in the University of Edinburgh’s Institute for Genetics and Cancer (IGC). At ELRIG’s Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provided a snapshot of drug discovery in Scotland.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

The Pharma Data

DECEMBER 31, 2020

where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. He also previously served as Global CMO at Taiho Pharmaceutical Company, Ltd. She most recently served as senior Medical Director at Ferring Pharmaceuticals in Copenhagen.

Engineering 52

Engineering Pharmaceuticals Virus Clinical Development 52

Conversations in Drug Development Trends

MAY 14, 2024

As the strategists for Worldwide Clinical Trials’ rare disease sponsors, we design customized solutions that make a difference in achieving successful outcomes. Our approach is informed by our combined 30+ years in rare disease clinical development and our time in various stakeholder roles, such as scientists, CRAs, and project managers.

Disease 52

Disease Clinical Trials Trials Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Production 52

Drug Discovery World

OCTOBER 10, 2022

Will an expansion in the use of effective digital biomarkers help improve the productivity of drug development in neuroscience? Increasingly, digital biomarkers are becoming more effectively used in the discovery and development of drugs that act in the central nervous system. The solution provided by digital biomarkers.

Drug Development 130

Drug Development Clinical Trials Drugs Trials 130

The Pharma Data

JANUARY 27, 2021

ET ) to discuss the results and next steps in clinical development of BI-1206. The Company’s validated, proprietary F.I.R.S.T The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals ( China ) Co., CET ( 11:30 a.m.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JULY 29, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co., Source link:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

JUNE 25, 2021

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. About Eisai Co.,

Disease 40

Disease Treatment Therapies FDA 40

Agency IQ

FEBRUARY 12, 2024

Far from just an outline of the work completed by Consortium members to date, the Playbook is a thoughtfully organized “how-to-guide” which walks readers through some of the major milestones of early clinical development in just over one hundred pages.

FDA 40

FDA Therapies Clinical Trials Virus 40

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA 52

RNA Protein Expression Therapies Disease 52

Drug Discovery World

MARCH 6, 2024

While this is an oversimplification, often patients who share a specific mutation in their tumour can be treated in a similar fashion as they will share this common mechanistic aetiology for their disease, and this is relatively easy to detect using modern sequencing and clinical genomics tools.

Clinical Trials 162

Clinical Trials Pharmaceutical Companies Disease Trials 162

The Pharma Data

JULY 8, 2021

is a leading global pharmaceutical company headquartered in Japan. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Follow us on social media – Twitter , LinkedIn , Facebook , YouTube.

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. However, recent advancements in the clinical use of recombinant DNA (rDNA) technology creates opportunities for changing this calculation and addressing a great, unmet medical need. What is the FDA Proposing to do?

Drug Development 52

Drug Development Disease Engineering Therapies 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

JANUARY 12, 2023

Here, Thomas reflects specifically on Anita Cooper’s prediction relating to the importance of clinical trials. . Following the launch of Protas, DDW spoke with Protas Chief Executive, Professor Sir Martin Landray, who echoed Cooper’s emphasis on the importance of clinical trial design.

Clinical Trials 243

Clinical Trials Drugs Trials Pharmaceutical Companies 243

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

Drug Discovery World

OCTOBER 30, 2023

This has huge implications for drug development and patient care. Only with such a high-resolution understanding of the mechanistic drivers of disease can diagnostic biomarkers and precision-targeted therapies be developed for conditions like endometriosis.

Treatment 182

Treatment Clinical Trials Disease Trials 182

PPD

DECEMBER 14, 2023

In this blog, we’ll explore the benefits associated with employing global resources across time zones for FSP engagements and how PPD ® FSP solutions utilize different regions to drive more efficient clinical development operations.

Clinical Development 52

Clinical Development Clinical Trials International Trials 52

Advarra

APRIL 4, 2024

Continuity of Experience Imagine a pharmaceutical company is embarking on a series of clinical trials for a particular therapeutic area, such as oncology or neurology. This continuity of experience enables the DSMB to provide the pharmaceutical company with more nuanced and informed recommendations throughout the entire program.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Trials FDA Trials 52

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What R&D efforts are needed to develop value-added medicines?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Production 52

The Connected Lab

APRIL 8, 2020

If we think about research in more traditional areas such as oncology, gastroenterology, and CNS disorders where large amounts of data have already been produced, AI, ML, and DL can help discover new compounds that could become new drugs, uncover or repurpose drugs, and improve the area of personalized medicine. Nature , vol.

Pharma Companies 52

Pharma Companies Laboratories FDA Approval Drugs 52

Molecule Blog

MARCH 17, 2023

The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Government Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

The collaboration aims to leverage Molecular Partners’ proprietary DARPin® technologies and Novartis’ broad expertise in global drug development, regulatory affairs, manufacturing and commercialization to rapidly advance the program in keeping with the unprecedented global urgency created by the pandemic.

Therapies 52

Therapies Virus Treatment Clinical Trials 52

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. drug development initiative from 2012 to February 2019. Before joining Acorda, Ms.

Clinical Trials 40

Clinical Trials Trials Production International 40

The Pharma Data

DECEMBER 15, 2020

(NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company’s business model is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52